To assess whether we could molecularly characterize the GEDI-captured CTCs, we performed proof-of-principle experiments in which prostate cancer cells were spiked into 1 ml of blood from a healthy donor, captured by the device and analyzed for the presence of androgen receptor (AR) point mutations or expression of TMPRSS2:ERG gene fusion protein. This evidence concerns the gene AR and prostate cancer.